Myeloperoxidase-mediated methionine oxidation promotes an amyloidogenic outcome for apolipoprotein A-I

Journal of Biological Chemistry

Volumn 290, Issue 17, 2015, Pages 10958-10971

  Chan, Gary K L ^a   Witkowski, Andrzej ^a   Gantz, Donald L ^b   Zhang, Tianqi O ^c   Zanni, Martin T ^c   Jayaraman, Shobini ^b   Cavigiolio, Giorgio ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; DEPOSITION; DISEASES; GLYCOPROTEINS; LIPOPROTEINS; OXIDATION; PROTEINS;

ACTIVATED MACROPHAGES; AMYLOID FIBRIL FORMATION; AMYLOIDOGENIC PROTEINS; APOLIPOPROTEIN A-I (APOA-I); ATHEROSCLEROTIC LESIONS; ATHEROSCLEROTIC PLAQUE; OXIDATIVE CONDITIONS; PROTEIN DESTABILIZATION;

IODINE;

AMYLOID PROTEIN; APOLIPOPROTEIN A1; HYDROGEN PEROXIDE; LEUCINE; METHIONINE; MYELOPEROXIDASE; AMYLOID; APOA1 PROTEIN, HUMAN; OXIDIZING AGENT; PEROXIDASE;

AMYLOIDOSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CIRCULAR DICHROISM; ELECTRON MICROSCOPY; FLUORESCENCE SPECTROSCOPY; IMMUNOBLOTTING; INCUBATION TEMPERATURE; INCUBATION TIME; INFLAMMATION; INFRARED SPECTROSCOPY; MASS SPECTROMETRY; MUTATION; OXIDATION; PH; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN STABILITY; PROTEIN STRUCTURE; ATHEROSCLEROSIS; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY;

AMYLOID; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; HUMANS; HYDROGEN PEROXIDE; HYDROGEN-ION CONCENTRATION; METHIONINE; OXIDANTS; OXIDATION-REDUCTION; PEROXIDASE; PLAQUE, ATHEROSCLEROTIC;

EID: 84928596578     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.630442     Document Type: Article

References (51)

1. Smith, J. D. (2010) Myeloperoxidase, inflammation, and dysfunctional high-density lipoprotein. J. Clin. Lipidol. 4, 382-388
2. Daugherty, A., Dunn, J. L., Rateri, D. L., and Heinecke, J. W. (1994) Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J. Clin. Invest. 94, 437-444
3. Nicholls, S. J., Zheng, L., and Hazen, S. L. (2005) Formation of dysfunctional high-density lipoprotein by myeloperoxidase. Trends Cardiovasc. Med. 15, 212-219
4. Shao, B., Oda, M. N., Bergt, C., Fu, X., Green, P. S., Brot, N., Oram, J. F., and Heinecke, J. W. (2006) Myeloperoxidase impairs ABCA1-dependent cholesterol efflux through methionine oxidation and site-specific tyrosine chlorination of apolipoprotein A-I. J. Biol. Chem. 281, 9001-9004
5. Shao, B., Tang, C., Heinecke, J. W., and Oram, J. F. (2010) Oxidation of apolipoprotein A-I by myeloperoxidase impairs the initial interactions with ABCA1 required for signaling and cholesterol export. J. Lipid Res. 51, 1849-1858
6. Zheng, L., Settle, M., Brubaker, G., Schmitt, D., Hazen, S. L., Smith, J. D., and Kinter, M. (2005) Localization of nitration and chlorination sites on apolipoprotein A-I catalyzed by myeloperoxidase in human atheroma and associated oxidative impairment in ABCA1-dependent cholesterol efflux from macrophages. J. Biol. Chem. 280, 38-47
7. Shao, B., Cavigiolio, G., Brot, N., Oda, M. N., and Heinecke, J. W. (2008) Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I. Proc. Natl. Acad. Sci. U.S.A. 105, 12224-12229
8. Shao, B., Pennathur, S., and Heinecke, J. W. (2012) Myeloperoxidase targets apolipoprotein A-I, the major high density lipoprotein protein, for site-specific oxidation in human atherosclerotic lesions. J. Biol. Chem. 287, 6375-6386
9. DiDonato, J. A., Huang, Y., Aulak, K. S., Even-Or, O., Gerstenecker, G., Gogonea, V., Wu, Y., Fox, P. L., Tang, W. H., Plow, E. F., Smith, J. D., Fisher, E. A., and Hazen, S. L. (2013) Function and distribution of apolipoprotein A1 in the artery wall are markedly distinct from those in plasma. Circulation 128, 1644-1655
10. Huang, Y., DiDonato, J. A., Levison, B. S., Schmitt, D., Li, L., Wu, Y., Buffa, J., Kim, T., Gerstenecker, G. S., Gu, X., Kadiyala, C. S., Wang, Z., Culley, M. K., Hazen, J. E., Didonato, A. J., Fu, X., Berisha, S. Z., Peng, D., Nguyen, T. T., Liang, S., Chuang, C. C., Cho, L., Plow, E. F., Fox, P. L., Gogonea, V., Tang, W. H., Parks, J. S., Fisher, E. A., Smith, J. D., and Hazen, S. L. (2014) An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat. Med. 20, 193-203
11. DiDonato, J. A., Aulak, K., Huang, Y., Wagner, M., Gerstenecker, G., Topbas, C., Gogonea, V., DiDonato, A. J., Tang, W. H., Mehl, R. A., Fox, P. L., Plow, E. F., Smith, J. D., Fisher, E. A., and Hazen, S. L. (2014) Site-specific nitration of apolipoprotein A-I at tyrosine 166 is both abundant within human atherosclerotic plaque and dysfunctional. J. Biol. Chem. 289, 10276-10292
12. Shao, B., Tang, C., Sinha, A., Mayer, P. S., Davenport, G. D., Brot, N., Oda, M. N., Zhao, X. Q., and Heinecke, J. W. (2014) Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidase. Circ. Res. 114, 1733-1742
13. Eriksson, M., Schönland, S., Yumlu, S., Hegenbart, U., von Hutten, H., Gioeva, Z., Lohse, P., Büttner, J., Schmidt, H., and Röcken, C. (2009) Hereditary apolipoprotein AI-associated amyloidosis in surgical pathology specimens: identification of three novel mutations in the APOA1 gene. J. Mol. Diagn. 11, 257-262
14. Raimondi, S., Guglielmi, F., Giorgetti, S., Di Gaetano, S., Arciello, A., Monti, D. M., Relini, A., Nichino, D., Doglia, S. M., Natalello, A., Pucci, P., Mangione, P., Obici, L., Merlini, G., Stoppini, M., Robustelli, P., Tartaglia, G. G., Vendruscolo, M., Dobson, C. M., Piccoli, R., and Bellotti, V. (2011) Effects of the known pathogenic mutations on the aggregation pathway of the amyloidogenic peptide of apolipoprotein A-I. J. Mol. Biol. 407, 465-476
15. Rowczenio, D., Dogan, A., Theis, J. D., Vrana, J. A., Lachmann, H. J., Wechalekar, A. D., Gilbertson, J. A., Hunt, T., Gibbs, S. D., Sattianayagam, P. T., Pinney, J. H., Hawkins, P. N., and Gillmore, J. D. (2011) Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I. Am. J. Pathol. 179, 1978-1987
16. Obici, L., Franceschini, G., Calabresi, L., Giorgetti, S., Stoppini, M., Merlini, G., and Bellotti, V. (2006) Structure, function and amyloidogenic propensity of apolipoprotein A-I. Amyloid 13, 191-205
17. Benson, M. D. (2005) Ostertag revisited: the inherited systemic amyloidoses without neuropathy. Amyloid 12, 75-87
18. Obici, L., Bellotti, V., Mangione, P., Stoppini, M., Arbustini, E., Verga, L., Zorzoli, I., Anesi, E., Zanotti, G., Campana, C., Viganò, M., and Merlini, G. (1999) The new apolipoprotein A-I variant Leu-174 → Ser causes hereditary cardiac amyloidosis, and the amyloid fibrils are constituted by the 93-residue N-terminal polypeptide. Am. J. Pathol. 155, 695-702
19. Amarzguioui, M., Mucchiano, G., Häggqvist, B., Westermark, P., Kavlie, A., Sletten, K., and Prydz, H. (1998) Extensive intimal apolipoprotein A1-derived amyloid deposits in a patient with an apolipoprotein A1 mutation. Biochem. Biophys. Res. Commun. 242, 534-539
20. Mangione, P., Sunde, M., Giorgetti, S., Stoppini, M., Esposito, G., Gianelli, L., Obici, L., Asti, L., Andreola, A., Viglino, P., Merlini, G., and Bellotti, V. (2001) Amyloid fibrils derived from the apolipoprotein A1 Leu174Ser variant contain elements of ordered helical structure. Protein Sci. 10, 187-199
21. Murphy, C., Kestler, D., Weiss, D., and Solomon, A. (2011) Non-hereditary apolipoprotein AI-associated pulmonary amyloid. Amyloid 18, 219-220
22. Solomon, A., Murphy, C. L., Kestler, D., Coriu, D., Weiss, D. T., Makovitzky, J., and Westermark, P. (2006) Amyloid contained in the knee joint meniscus is formed from apolipoprotein A-I. Arthritis Rheum. 54, 3545-3550
23. Loavenbruck, A. J., Chaudhry, V., Zeldenrust, S. R., Spinner, R. J., Theis, J. D., and Klein, C. J. (2012) Mass spectrometry analysis reveals non-mutated apolipoprotein A1 lumbosacral radiculoplexus amyloidoma. Muscle Nerve 46, 817-822
24. Audet, A., Côté, N., Couture, C., Bossé, Y., Després, J. P., Pibarot, P., and Mathieu, P. (2012) Amyloid substance within stenotic aortic valves promotes mineralization. Histopathology 61, 610-619
25. Westermark, P., Mucchiano, G., Marthin, T., Johnson, K. H., and Sletten, K. (1995) Apolipoprotein A1-derived amyloid in human aortic atherosclerotic plaques. Am. J. Pathol. 147, 1186-1192
26. Mucchiano, G. I., Häggqvist, B., Sletten, K., and Westermark, P. (2001) Apolipoprotein A-1-derived amyloid in atherosclerotic plaques of the human aorta. J. Pathol. 193, 270-275
27. Mucchiano, G. I., Jonasson, L., Häggqvist, B., Einarsson, E., and Westermark, P. (2001) Apolipoprotein A-I-derived amyloid in atherosclerosis. Its association with plasma levels of apolipoprotein A-I and cholesterol. Am. J. Clin. Pathol. 115, 298-303
28. Cornwell, G. G., 3rd, Murdoch, W. L., Kyle, R. A., Westermark, P., and Pitkänen, P. (1983) Frequency and distribution of senile cardiovascular amyloid: a clinicopathologic correlation. Am. J. Med. 75, 618-623
29. Mucchiano, G., Cornwell, G. G., 3rd, and Westermark, P. (1992) Senile aortic amyloid: evidence for two distinct forms of localized deposits. Am. J. Pathol. 140, 871-877
30. Wong, Y. Q., Binger, K. J., Howlett, G. J., and Griffin, M. D. (2010) Methionine oxidation induces amyloid fibril formation by full-length apolipoprotein A-I. Proc. Natl. Acad. Sci. U.S.A. 107, 1977-1982
31. Tubb, M. R., Smith, L. E., and Davidson, W. S. (2009) Purification of recombinant apolipoproteins A-I and A-IV and efficient affinity tag cleavage by tobacco etch virus protease. J. Lipid Res. 50, 1497-1504
32. Schumaker, V. N., and Puppione, D. L. (1986) Sequential flotation ultracentrifugation. Methods Enzymol. 128, 155-170
33. Wetterau, J. R., and Jonas, A. (1982) Effect of dipalmitoylphosphatidylcholine vesicle curvature on the reaction with human apolipoprotein A-I. J. Biol. Chem. 257, 10961-10966
34. Rogers, D. P., Roberts, L. M., Lebowitz, J., Datta, G., Anantharamaiah, G. M., Engler, J. A., and Brouillette, C. G. (1998) The lipid-free structure of apolipoprotein A-I: effects of amino-terminal deletions. Biochemistry 37, 11714-11725
35. Jayaraman, S., Abe-Dohmae, S., Yokoyama, S., and Cavigiolio, G. (2011) Impact of self-association on function of apolipoprotein A-I. J. Biol. Chem. 286, 35610-35623
36. Shao, B., and Heinecke, J. W. (2008) Using tandem mass spectrometry to quantify site-specific chlorination and nitration of proteins: model system studies with high-density lipoprotein oxidized by myeloperoxidase. Methods Enzymol. 440, 33-63
37. Coelho-Cerqueira, E., Pinheiro, A. S., and Follmer, C. (2014) Pitfalls associated with the use of thioflavin-T to monitor anti-fibrillogenic activity. Bioorg. Med. Chem. Lett. 24, 3194-3198
38. Mehta, R., Gantz, D. L., and Gursky, O. (2003) Human plasma high-density lipoproteins are stabilized by kinetic factors. J. Mol. Biol. 328, 183-192
39. Klunk, W. E., Jacob, R. F., and Mason, R. P. (1999) Quantifying amyloid β-peptide (Aαβ) aggregation using the Congo red-Aβ (CR-aβ) spectrophotometric assay. Anal. Biochem. 266, 66-76
40. Srinivasan, S., Patke, S., Wang, Y., Ye, Z., Litt, J., Srivastava, S. K., Lopez, M. M., Kurouski, D., Lednev, I. K., Kane, R. S., and Colón, W. (2013) Pathogenic serum amyloid A 1.1 shows a long oligomer-rich fibrillation lag phase contrary to the highly amyloidogenic non-pathogenic SAA2.2. J. Biol. Chem. 288, 2744-2755
41. Kayed, R., Head, E., Sarsoza, F., Saing, T., Cotman, C. W., Necula, M., Margol, L., Wu, J., Breydo, L., Thompson, J. L., Rasool, S., Gurlo, T., Butler, P., and Glabe, C. G. (2007) Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol. Neurodegener. 2, 18
42. Andreola, A., Bellotti, V., Giorgetti, S., Mangione, P., Obici, L., Stoppini, M., Torres, J., Monzani, E., Merlini, G., and Sunde, M. (2003) Conformational switching and fibrillogenesis in the amyloidogenic fragment of apolipoprotein a-I. J. Biol. Chem. 278, 2444-2451
43. Brahms, S., Brahms, J., Spach, G., and Brack, A. (1977) Identification of β,β-turns and unordered conformations in polypeptide chains by vacuum ultraviolet circular dichroism. Proc. Natl. Acad. Sci. U.S.A. 74, 3208-3212
44. Zandomeneghi, G., Krebs, M. R., McCammon, M. G., and Fändrich, M. (2004) FTIR reveals structural differences between native β-sheet proteins and amyloid fibrils. Protein Sci. 13, 3314-3321
45. Buchanan, L. E., Dunkelberger, E. B., Tran, H. Q., Cheng, P. N., Chiu, C. C., Cao, P., Raleigh, D. P., de Pablo, J. J., Nowick, J. S., and Zanni, M. T. (2013) Mechanism of IAPP amyloid fibril formation involves an intermediate with a transient β-sheet. Proc. Natl. Acad. Sci. U.S.A. 110, 19285-19290
46. Middleton, C. T., Marek, P., Cao, P., Chiu, C. C., Singh, S., Woys, A. M., de Pablo, J. J., Raleigh, D. P., and Zanni, M. T. (2012) Two-dimensional infrared spectroscopy reveals the complex behaviour of an amyloid fibril inhibitor. Nat. Chem. 4, 355-360
47. Kim, Y. S., Liu, L., Axelsen, P. H., and Hochstrasser, R. M. (2009) 2D IR provides evidence for mobile water molecules in β-amyloid fibrils. Proc. Natl. Acad. Sci. U.S.A. 106, 17751-17756
48. Moran, S. D., Woys, A. M., Buchanan, L. E., Bixby, E., Decatur, S. M., and Zanni, M. T. (2012) Two-dimensional IR spectroscopy and segmental 13C labeling reveals the domain structure of human γD-crystallin amyloid fibrils. Proc. Natl. Acad. Sci. U.S.A. 109, 3329-3334
49. Petrlova, J., Duong, T., Cochran, M. C., Axelsson, A., Mörgelin, M., Roberts, L. M., and Lagerstedt, J. O. (2012) The fibrillogenic L178H variant of apolipoprotein A-I forms helical fibrils. J. Lipid Res. 53, 390-398
50. Matsunaga, T., Hiasa, Y., Yanagi, H., Maeda, T., Hattori, N., Yamakawa, K., Yamanouchi, Y., Tanaka, I., Obara, T., and Hamaguchi, H. (1991) Apolipoprotein A-I deficiency due to a codon 84 nonsense mutation of the apolipoprotein A-I gene. Proc. Natl. Acad. Sci. U.S.A. 88, 2793-2797
51. Miti, T., Mulaj, M., Schmit, J. D., and Muschol, M. (2015) Stable, metastable, and kinetically trapped amyloid aggregate phases. Biomacromolecules 16, 326-335